SCHEMBL525075

SCHEMBL525075

COc1ccc(Cl)cc1-c1coc2c1C(=O)CCC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
ALDH1A1 P00352 10/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 6/20 0.40
NPSR1 Q6W5P4 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
USP2 O75604 2/20 0.39
KDM4E B2RXH2 5/20 0.38
RAB9A P51151 2/20 0.38
POLB P06746 1/20 0.38
BRD4 O60885 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PRNP P04156 1/20 0.36
PPARG P37231 1/20 0.36
MAPK10 P53779 1/20 0.36
NCOA2 Q15596 1/20 0.36
NCOA1 Q15788 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL525293 0.77 HSD17B1 (0.39) ALDH1A1MAPTHPGDNPSR1SMN1; SMN2
SCHEMBL525638 0.76 BRD4 (0.43) TSHRLMNAHTTALDH1A1MAPT
SCHEMBL525296 0.75 BRD4 (0.50) LMNAALDH1A1MAPTNPSR1SMN1; SMN2
SCHEMBL524971 0.74 ALDH1A1 (0.40) ALDH1A1MAPTSMN1; SMN2POLBBRD4
SCHEMBL525420 0.74 EGFR (0.43) ALDH1A1HPGDKDM4E
SCHEMBL525386 0.72 BRD4 (0.47) ALDH1A1MAPTSMN1; SMN2POLBBRD4
SCHEMBL525555 0.71 BRD4 (0.52) LMNAALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL7699644 0.71 ALDH1A1 (0.56) LMNAALDH1A1HPGDNPSR1SMN1; SMN2
SCHEMBL525309 0.69 DYRK1A (0.40) TSHRALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL525730 0.69 SRC (0.43) HTTALDH1A1MAPTHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9315482-B2 Derivatives useful as antiviral agents INSTITUT PASTEUR (FR) 2016-04-19 US claimed
US-20130210886-A1 Novel Derivatives Useful as Antiviral Agents INSTITUT PASTEUR (FR) 2013-08-15 US claimed
EP-2598495-A1 NOVEL DERIVATIVES USEFUL AS ANTIVIRAL AGENTS Institut Pasteur (FR) 2013-06-05 EP claimed
EP-2420495-A1 Novel derivatives useful as antiviral agents Institut Pasteur (FR) 2012-02-22 EP claimed
WO-2012014181-A1 NOVEL DERIVATIVES USEFUL AS ANTIVIRAL AGENTS INSTITUT PASTEUR (FR) 2012-02-02 WO claimed
US-9315482-B2 Derivatives useful as antiviral agents INSTITUT PASTEUR (FR) 2016-04-19 US disclosed
US-20130210886-A1 Novel Derivatives Useful as Antiviral Agents INSTITUT PASTEUR (FR) 2013-08-15 US disclosed
EP-2598495-A1 NOVEL DERIVATIVES USEFUL AS ANTIVIRAL AGENTS Institut Pasteur (FR) 2013-06-05 EP disclosed
EP-2420495-A1 Novel derivatives useful as antiviral agents Institut Pasteur (FR) 2012-02-22 EP disclosed
WO-2012014181-A1 NOVEL DERIVATIVES USEFUL AS ANTIVIRAL AGENTS INSTITUT PASTEUR (FR) 2012-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210886-A1 Novel Derivatives Useful as Antiviral Agents MAVS, IRF3, IFNAR1 TSHR 2624/4885LMNA 1102/4885HTT 3542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.